AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
-$1.07 today
- Market cap
- $1.40B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
Volume 0.57M
Average 0.76M
ANAB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
AnaptysBio, Inc.NASDAQ: ANAB
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$31.38M, compared with -$20.62M a year earlier. Trailing-twelve-month EBITDA was $58.49M.
Context
- EBITDA amounted to 29.5% of revenue in FY2025, down 72.1 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $219.06M (+216.3%) for the fiscal year ending Dec 2026, a step up from the +174.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$31.38M-144.8% QoQ
- Last fiscal yearDec 2025
- $69.25M+174.7% YoY
- LTMMar 2026
- $58.49M+176.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -52.2% | +40.2% | +92.4 pp |
| 1 year | +174.7% | +216.3% | +41.7 pp |
| 3-year CAGR | — | +68.2% | — |
| 5-year CAGR | +40.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 69.25M USD
- Year-over-year change
- +174.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 69.25M | +174.7% |
| FY2024 | 2024-12-31 | (92.74M) | +40.7% |
| FY2023 | 2023-12-31 | (156.42M) | -48.6% |
| FY2022 | 2022-12-31 | (105.26M) | -89.0% |
| FY2021 | 2021-12-31 | (55.71M) | — |
EBITDA vs competitors
How ANAB compares with its peers on the latest reported figures
- ANAB's LTM Mar 2026 EBITDA of $58.49M is the highest of the 10 companies compared; the peer median is -$84.44M.
- Its year-over-year change of +176.6% is the highest of 10, against a peer median of -17.1%.
- EBITDA amounts to 25.2% of revenue for ANAB, versus a peer median of 1197.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $58.49M | +176.6% | — | 25.2% | |
| LTM Mar 2026 | $22.15M | +154.8% | — | 41.2% | |
| LTM Jun 2026 | -$29.53M | +74.2% | — | 1550.9% | |
| FY2025 | -$54.58M | -270.2% | — | 85279.7% | |
| LTM Mar 2026 | -$70.61M | -31.5% | — | 843.9% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M | -35.4% | — | — |
| LTM Jun 2026 | -$123.6M | -14.3% | — | 117.7% | |
| LTM Mar 2026 | -$193.41M | -17.1% | — | — | |
| LTM Mar 2026 | -$245.81M | -69.1% | — | — | |
| LTM Sep 2026 | -$509.88M | -10.4% | — | 7186.4% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ANAB) | -$84.44M | -17.1% | — | 1197.4% | |
Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.18M | 10.29M | 17.16M | 91.28M | 234.6M |
| Cost of Revenue | 98.5M | 88.8M | 132.28M | 163.84M | 2.42M |
| Gross Profit | (35.32M) | (78.51M) | (115.13M) | (72.56M) | 232.18M |
| Gross Margin | -55.9% | -763.2% | -671.0% | -79.5% | 99.0% |
| Research & Development | 98.5M | 88.8M | 139.62M | 163.84M | 135.97M |
| Selling, General & Admin | 21.49M | 36.64M | 41.95M | 42.39M | 50.74M |
| Operating Expenses | 21.49M | 36.64M | 49.29M | 42.39M | 184.28M |
| Depreciation & Amortization | 2.09M | 2.34M | 652K | 2.4M | 2.42M |
| EBITDA | (55.71M) | (105.26M) | (156.42M) | (92.74M) | 69.25M |
| EBITDA Margin | -88.2% | -1023.2% | -911.7% | -101.6% | 29.5% |
| Operating Income | (56.81M) | (115.15M) | (164.41M) | (114.95M) | 47.9M |
| Operating Margin | -89.9% | -1119.4% | -958.3% | -125.9% | 20.4% |
| Interest Income | 431K | 7.55M | 18.87M | 19.79M | 13.5M |
| Interest Expense | 1.45M | 21.11M | 18.08M | 50.09M | 79.89M |
| Other Income / Expenses | (982K) | (13.55M) | 788K | (30.28M) | (60.96M) |
| Income Before Tax | (57.8M) | (128.7M) | (163.62M) | (145.23M) | (13.07M) |
| Pre-Tax Margin | -91.5% | -1251.1% | -953.7% | -159.1% | -5.6% |
| Income Tax Expense | 0 | 24K | (4K) | 3K | 164K |
| Net Income | (57.8M) | (128.72M) | (163.62M) | (145.23M) | (13.23M) |
| Net Margin | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
| EPS (Basic) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| EPS (Diluted) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| Weighted Avg Shares | 27.43M | 28.17M | 26.92M | 28.38M | 27.79M |
| Weighted Avg Shares (Diluted) | 27.43M | 28.17M | 26.92M | 28.38M | 31.34M |
AnaptysBio, Inc.
NASDAQ:ANAB
Intrinsic Alpha fair value
Locked
Current Price
$47.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.